Citadel Advisors’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-74,217
| Closed | -$42K | – | 10255 |
|
|
2019
Q3 | $42K | Sell |
74,217
-10,990
| -13% | -$6.12K | ﹤0.01% | 8757 |
|
|
2019
Q2 | $53K | Buy |
85,207
+10,221
| +14% | +$7.34K | ﹤0.01% | 8718 |
|
|
2019
Q1 | $81K | Buy |
74,986
+54,025
| +258% | +$52.8K | ﹤0.01% | 8632 |
|
|
2018
Q4 | $9K | Buy |
+20,961
| New | +$19.1K | ﹤0.01% | 8951 |
|
|
2018
Q2 | – | Sell |
-32,480
| Closed | -$12K | – | 9700 |
|
|
2018
Q1 | $12K | Buy |
+32,480
| New | +$21.3K | ﹤0.01% | 8174 |
|
|
2017
Q1 | – | Sell |
-22,829
| Closed | -$23K | – | 8545 |
|
|
2016
Q4 | $23K | Buy |
22,829
+5,388
| +31% | +$6.05K | ﹤0.01% | 7057 |
|
|
2016
Q3 | $18K | Buy |
+17,441
| New | +$21.1K | ﹤0.01% | 7092 |
|
|
2016
Q2 | – | Sell |
-31,819
| Closed | -$42K | – | 7958 |
|
|
2016
Q1 | $42K | Buy |
+31,819
| New | +$42.6K | ﹤0.01% | 6295 |
|
|
2015
Q4 | – | Sell |
-12,087
| Closed | -$19K | – | 9767 |
|
|
2015
Q3 | $19K | Buy |
+12,087
| New | +$23.3K | ﹤0.01% | 8220 |
|
Citadel Advisors's CELGZ Position: Q4 2019 in Review
Citadel Advisors sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 74,217 shares — an estimated $42K sold.
Citadel Advisors first reported a position in CELGZ in Q3 2015 and held it in 9 quarters. The position peaked at $81K in Q1 2019. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.
- Citadel Advisors reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
- Citadel Advisors sold 74,217 Celgene Corporation Contingent Value Rights shares in Q4 2019, an estimated $42K.
- Citadel Advisors first reported a position in Celgene Corporation Contingent Value Rights in Q3 2015 and held it in 9 quarters.
- Citadel Advisors's Celgene Corporation Contingent Value Rights position peaked at $81K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.